Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Frey

Showing results (351-360 of 368) with videos related to

Pageof 37
Sort By:
The Journal of Infectious Diseases|January 26, 2023
A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy AdultsJustin R Ortiz, David I Bernstein, Daniel F Hoft, et al.
Vaccine|November 30, 2025
Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccinationSharon E Frey, Lindsey R Baden, Hana M El Sahly, et al.
Vaccine|July 6, 2015
Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjectsSharon E Frey, Anna Wald, Srilatha Edupuganti, et al.
The Lancet. Infectious Diseases|March 23, 2013
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trialJanet E McElhaney, Jiri Beran, Jeanne-Marie Devaster, et al.
Vaccine|March 19, 2025
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of ageTheresa E Hegmann, Emmanuel B Walter, Michael J Smith, et al.
Vaccine|January 5, 2025
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimensHana M El Sahly, Evan J Anderson, Lisa A Jackson, et al.
Science (New York, N.Y.)|June 9, 2012
Massive phytoplankton blooms under Arctic sea iceKevin R Arrigo, Donald K Perovich, Robert S Pickart, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
Cancer Treatment Reviews|December 5, 2017
Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent and young adult cancer: Recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup ConsortiumS C Clement, L C M Kremer, F A Verburg, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
Pageof 37

Showing results (351-360 of 368) with videos related to

Sort By:
Pageof 37
The Journal of Infectious Diseases|January 26, 2023
A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy AdultsJustin R Ortiz, David I Bernstein, Daniel F Hoft, et al.
Vaccine|November 30, 2025
Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccinationSharon E Frey, Lindsey R Baden, Hana M El Sahly, et al.
Vaccine|July 6, 2015
Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjectsSharon E Frey, Anna Wald, Srilatha Edupuganti, et al.
The Lancet. Infectious Diseases|March 23, 2013
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trialJanet E McElhaney, Jiri Beran, Jeanne-Marie Devaster, et al.
Vaccine|March 19, 2025
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of ageTheresa E Hegmann, Emmanuel B Walter, Michael J Smith, et al.
Vaccine|January 5, 2025
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimensHana M El Sahly, Evan J Anderson, Lisa A Jackson, et al.
Science (New York, N.Y.)|June 9, 2012
Massive phytoplankton blooms under Arctic sea iceKevin R Arrigo, Donald K Perovich, Robert S Pickart, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
Cancer Treatment Reviews|December 5, 2017
Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent and young adult cancer: Recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup ConsortiumS C Clement, L C M Kremer, F A Verburg, et al.
Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
Pageof 37